论文部分内容阅读
目的:研究阿德福韦酯治疗乙肝患者肝硬化失代偿期的临床疗效。方法:选取重庆市永川区人民医院2012年3月-2014年12月收治的73例肝硬化失代偿期患者,随机分为对照组36例与观察组37例。对于照组给予常规保肝治疗法;观察组在此基础上给予阿德福韦酯实施治疗。结果:治疗后两组患者谷氨酸氨基转移酶(ALT)、总胆红素(TBIL)、血白蛋白(ALB)及Child-Pugh分数较治疗前均有所改善,且观察组的改善情况显著优于对照组;观察组并发症发生率明显低于对照组;观察组HBV-DNA转阴率明显高于对照组。结论:联合应用阿德福韦酯可提高肝硬化失代偿期的临床治疗效果。
Objective: To study the clinical efficacy of adefovir dipivoxil in the treatment of decompensated liver cirrhosis patients. Methods: Seventy-three patients with decompensated liver cirrhosis who were admitted to Yongchuan District People’s Hospital of Chongqing from March 2012 to December 2014 were randomly divided into control group (36 cases) and observation group (37 cases). For the group given conventional hepatoprotective therapy; observation group on this basis to give adefovir dipivoxil treatment. Results: The ALT, TBIL, ALB and Child-Pugh scores of the two groups were improved after treatment, and the improvement of the observation group Significantly higher than the control group; the incidence of complications in the observation group was significantly lower than the control group; the negative rate of HBV-DNA in the observation group was significantly higher than that of the control group. Conclusion: The combination of adefovir dipivoxil can improve the clinical efficacy of decompensated cirrhosis.